Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Thrombotic Thrombocytopenic Purpura (TTP) Treatment & Management

  • Author: Theodore Wun, MD, FACP; Chief Editor: Srikanth Nagalla, MBBS, MS, FACP  more...
 
Updated: Jun 20, 2016
 

Medical Care

Therapy should be initiated if the diagnosis of thrombotic thrombocytopenic purpura (TTP) is seriously considered.[11] Only a minority of patients (20-30%) present with the classic pentad. The presence of microangiopathic hemolytic anemia (schistocytes, elevated lactate dehydrogenase [LDH] level, and indirect hyperbilirubinemia) and thrombocytopenia in the absence of other obvious causes (eg, disseminated intravascular coagulation, malignant hypertension) is justification to begin total plasma exchange—preferably within 4–8 hours, according to British TTP guidelines.[12]

Shah et al have described the use of ADAMTS13 (thrombospondin type 1 motif, member 13) measurement to guide the use of plasma exchange in patients with TTP. In their study, plasma exchange was initiated only in patients with ADAMTS13 activity <10%. Not initiating plasma exchange in patients without severe ADAMTS13 deficiency—or discontinuing plasma exchange after a short course, when baseline ADAMTS13 levels became available and were found to be >11%—proved to be a safe approach, with no increase in mortality.[13]

Because TTP is a medical emergency, long turnaround times for ADAMTS13 activity assay results preclude the use of this test in the decision whether to start plasma exchange. Connell et al reported a significant reduction in plasma utilization for patients with suspected TTP, with no increase in mortality, with the implementation of an assay with a rapid turnaround time.[14]

Plasma exchange with fresh frozen plasma is the therapy of choice for TTP. Octaplas is a pooled plasma (human) that has been treated with a solvent detergent process. This blood product provides a viable alternative to single-donor fresh-frozen plasma and provides a reduced risk of certain viral transmissions. Replacement with normal saline and albumin is not adequate. When immediate plasma exchange is not available, simple plasma infusion can be performed until the patient can be transferred to a facility that performs plasma exchange.[15]

Usually, at least five plasma exchanges are performed in the first 10 days. The authors' routine is to exchange 1.5 plasma volumes with each exchange for five consecutive days, although some physicians exchange one predicted plasma volume. If no response to exchange is observed, a second course of five exchanges can be performed. Others have used a course of at least seven exchanges during the first nine days of therapy. In the author's cohort, the vast majority of responses were seen within the first 10 plasma exchanges. However, a few patients took up to 15 exchanges to respond.

Plasma exchange generally is well tolerated, although some patients do have intravenous access problems, hypotension, and reactions to plasma. Hypotension can result from the necessary extracorporeal volume in the apheresis device. For small patients, this may represent a considerable fraction of their total blood volume. Using a smaller bowl and/or priming the machine with colloid can circumvent this problem. In addition, the patient can be given a small colloid bolus prior to beginning the procedure.

Complete response criteria differ depending on the investigator, but they generally include the following:

  • Resolution of neurologic symptoms
  • Normalization of hemoglobin, platelet count, LDH, and bilirubin
  • Normalization of creatinine

Adequate initial response is fulfilled if neurologic signs and symptoms disappear, the platelet count climbs to greater than 50,000/μL, and the LDH level declines. In patients who respond to plasma exchange, the mean time to resolution of neurologic changes is approximately 3 days, to a normal LDH is 5 days, to a normal platelet count is 10 days, and to normal renal function is 15 days.

The total number of exchanges necessary for sustained response is not established. Anecdotally, the rate of relapse is increased if plasma exchange is stopped abruptly, although no prospective, or even retrospective, study has shown this to be true. Regardless, many apheresis services taper the exchanges from three per week to one per week before stopping therapy. In the author's experience, a direct correlation existed between the number of exchanges required to reach a platelet count of 150,000/μL and the risk of relapse.

Marn Pernat et al reported their 11-year experience with membrane plasma exchange for the treatment of TTP.[16] Therapy was immediately initiated in 56 patients, then once or twice daily until the platelet counts were normalized, with an average number of 19 ± 17 plasma exchanges per patient. Nearly 1100 plasma exchange procedures were performed, in which 1-1.5 plasma volumes (3606 ± 991 mL) were replaced with fresh frozen plasma, with an average duration of 23 ± 17 days.[16] Although renal impairment was found in 36% of patients, 93% (52/56) had an excellent response to the therapy, of whom 86% (48 patients) reached complete remission (platelet count > 100 × 109/L).[16]

There were four deaths soon after plasma exchange therapy was initiated (post one to three procedures), and in the follow-up period, of six patients who had achieved complete remission and subsequently had one to five relapses each year, one died of acute hemolytic reaction during tapering of the therapy. Splenectomy was performed on three patients.[16] Overall, Marn Pernat et al did not find serious side effects with plasma exchange therapy in their cohort of 1066 patients.

In patients whose TTP is refractory to plasma exchange, using cryopoor plasma (or cryosupernatant) has sometimes led to a response. This is fresh frozen plasma that has had the cryoprecipitate removed and is thus depleted of high-molecular-weight von Willebrand multimers, which have a pathogenic role in TTP. However, a meta-analysis of three trials that compared plasma exchange using cryosupernatant plasma with plasma exchange using fresh frozen plasma showed no difference between the two.[17]

Corticosteroids are commonly given to patients with TTP. Responses to corticosteroid therapy alone have been documented.

Increasing evidence supports the use of the anti-CD20 monoclonal antibody rituximab in cases of TTP refractory to plasma exchange, with resolution of acute disease and prolonged remission.[18, 8, 19, 20] British guidelines recommend offering rituximab to patients with refractory or relapsing immune-mediated TTP, and considering rituximab as part of first-line therapy, along with plasma exchange and steroids, in acute idiopathic TTP with neurological/cardiac pathology, as those cases are associated with high mortality.[12]

Patriquin et al reported successful use of the proteasome inhibitor bortezomib in patients with TTP refractory to intensive therapy. Five of the six patients in this study achieved complete remission with bortezomib; one died of cardiac arrest due to underlying disease. No treatment-related adverse events were observed.[21]

The use of aspirin and dipyridamole, although part of standard therapy in the past, has fallen out of favor. Vincristine, a vinca alkaloid generally used as chemotherapy, also has been shown to be useful in refractory patients. Complete response has been reported in one patient with TTP treated with vincristine alone. Finally, reports have shown patients improving with therapy using a staphylococcal protein A column (Prosorba), which presumably acts by removing immune complexes.

Platelet transfusions should be avoided unless life-threatening (usually central nervous system) bleeding is present. Anecdotal reports have documented myocardial infarction and stroke following platelet transfusion in patients with TTP. In a single-institution review, Zhou et al found that of 233 patients with TTP, 15 patients had received platelet transfusions, with variable responses; in general, platelet transfusion was not detrimental, but its efficacy was uncertain.[22]

In TTP triggered by underlying infection, treatment of the infection may help improve the outcome. Gringauz et al report a case of refractory TTP, in a patient with active chronic gastritis positive for Helicobacter pylori, in which the TTP resolved completely after eradication of the infection.[23]

Caplacizumab, an anti–von Willebrand factor humanized single-variable-domain immunoglobulin, may prevent microthrombus formation by blocking the binding of platelets to ultralarge von Willebrand factor multimers. In a randomized phase 2 study in 76 patients with acute acquired TTP, the addition of caplacizumab to stand-of-care treatment led to faster normalization of the platelet count than did placebo.[24] A phase 3 trial of caplacizumab in acquired TTP is currently recruiting participants.[25]

Next

Consultations

Consultations to consider include the following:

  • Hematologist
  • Apheresis service, if different from the hematologist
  • Surgical colleagues, for placement of a central venous access device adequate for apheresis and for splenectomy, which has been used in refractory cases of TTP
  • Nephrologist, if renal impairment warrants dialysis
Previous
Next

Diet and Activity

Other than a renal diet if the patient is azotemic or uremic, no diet is indicated for this condition. Activity should be restricted if the patient has altered mental status or bleeding.

Previous
 
 
Contributor Information and Disclosures
Author

Theodore Wun, MD, FACP Professor of Medicine, Professor of Pathology and Laboratory Medicine, University of California Davis School of Medicine; Chief of Hematology/Oncology, Program Director, Veterans Affairs Northern California Health Care System; Medical Director, University of California Davis CCRC

Theodore Wun, MD, FACP is a member of the following medical societies: American Association of Blood Banks, American Society for Blood and Marrow Transplantation, American College of Physicians, American Federation for Medical Research, American Society of Hematology, SWOG

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Marcel E Conrad, MD Distinguished Professor of Medicine (Retired), University of South Alabama College of Medicine

Marcel E Conrad, MD is a member of the following medical societies: Alpha Omega Alpha, American Association for the Advancement of Science, American Association of Blood Banks, American Chemical Society, American College of Physicians, American Physiological Society, American Society for Clinical Investigation, American Society of Hematology, Association of American Physicians, Association of Military Surgeons of the US, International Society of Hematology, Society for Experimental Biology and Medicine, SWOG

Disclosure: Partner received none from No financial interests for none.

Chief Editor

Srikanth Nagalla, MBBS, MS, FACP Associate Professor of Medicine, Division of Hematology and Oncology, UT Southwestern Medical Center

Srikanth Nagalla, MBBS, MS, FACP is a member of the following medical societies: American Society of Hematology, Association of Specialty Professors

Disclosure: Nothing to disclose.

Acknowledgements

Wadie F Bahou, MD Chief, Division of Hematology, Hematology/Oncology Fellowship Director, Professor, Department of Internal Medicine, State University of New York at Stony Brook

Wadie F Bahou, MD is a member of the following medical societies: American Society of Hematology

Disclosure: Nothing to disclose.

References
  1. Tsai HM. Thrombotic thrombocytopenic purpura and the atypical hemolytic uremic syndrome: an update. Hematol Oncol Clin North Am. 2013 Jun. 27(3):565-84. [Medline].

  2. Ferrari S, Mudde GC, Rieger M, Veyradier A, Kremer Hovinga JA, Scheiflinger F. IgG-subclass distribution of anti-ADAMTS13 antibodies in patients with acquired thrombotic thrombocytopenic purpura. J Thromb Haemost. 2009 Aug 11. [Medline].

  3. Mariotte E, Azoulay E, Galicier L, Rondeau E, Zouiti F, Boisseau P, et al. Epidemiology and pathophysiology of adulthood-onset thrombotic microangiopathy with severe ADAMTS13 deficiency (thrombotic thrombocytopenic purpura): a cross-sectional analysis of the French national registry for thrombotic microangiopathy. Lancet Haematol. 2016 May. 3 (5):e237-45. [Medline].

  4. Lowes R. FDA Okays Blood Plasma Product for Clotting Disorders. Medscape Medical News. January 17, 2013. Available at http://www.medscape.com/viewarticle/777822. Accessed: January 31, 2013.

  5. Vesely SK, George JN, Lammle B, et al. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood. 2003 Jul 1. 102(1):60-8. [Medline].

  6. Sauna ZE, Okunji C, Hunt RC, et al. Characterization of conformation-sensitive antibodies to ADAMTS13, the von Willebrand cleavage protease. PLoS One. 2009 Aug 5. 4(8):e6506. [Medline]. [Full Text].

  7. Miller DP, Kaye JA, Shea K, Ziyadeh N, Cali C, Black C, et al. Incidence of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome. Epidemiology. 2004 Mar. 15 (2):208-15. [Medline].

  8. Scully M, Thomas M, Underwood M, Watson H, Langley K, Camilleri RS, et al. Thrombotic thrombocytopenic purpura and pregnancy: presentation, management, and subsequent pregnancy outcomes. Blood. 2014 Jul 10. 124(2):211-9. [Medline].

  9. Bouw MC, Dors N, van Ommen H, Ramakers-van Woerden NL. Thrombotic thrombocytopenic purpura in childhood. Pediatr Blood Cancer. 2009 Jun 18. 53(4):537-542. [Medline].

  10. Wu N, Liu J, Yang S, Kellett ET, Cataland SR, Li H, et al. Diagnostic and prognostic values of ADAMTS13 activity measured during daily plasma exchange therapy in patients with acquired thrombotic thrombocytopenic purpura. Transfusion. 2014 Jun 23. [Medline].

  11. Coppo P, Veyradier A. Current management and therapeutical perspectives in thrombotic thrombocytopenic purpura. Presse Med. 2012 Mar. 41(3 Pt 2):e163-76. [Medline].

  12. [Guideline] Scully M, Hunt BJ, Benjamin S, Liesner R, Rose P, Peyvandi F, et al. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol. 2012 Aug. 158 (3):323-35. [Medline]. [Full Text].

  13. Shah N, Rutherford C, Matevosyan K, Shen YM, Sarode R. Role of ADAMTS13 in the management of thrombotic microangiopathies including thrombotic thrombocytopenic purpura (TTP). Br J Haematol. 2013 Nov. 163 (4):514-9. [Medline].

  14. Connell NT, Cheves T, Sweeney JD. Effect of ADAMTS13 activity turnaround time on plasma utilization for suspected thrombotic thrombocytopenic purpura. Transfusion. 2015 Oct 12. [Medline].

  15. Duffy SM, Coyle TE. Platelet transfusions and bleeding complications associated with plasma exchange catheter placement in patients with presumed thrombotic thrombocytopenic purpura. J Clin Apher. 2013 May 30. [Medline].

  16. Marn Pernat A, Buturovic-Ponikvar J, Kovac J, et al. Membrane plasma exchange for the treatment of thrombotic thrombocytopenic purpura. Ther Apher Dial. 2009 Aug. 13(4):318-21. [Medline].

  17. Michael M, Elliott EJ, Craig JC, Ridley G, Hodson EM. Interventions for hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: a systematic review of randomized controlled trials. Am J Kidney Dis. 2009 Feb. 53(2):259-72. [Medline].

  18. Fakhouri F, Vernant JP, Veyradier A, et al. Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases. Blood. 2005 Sep 15. 106(6):1932-7. [Medline].

  19. Froissart A, Buffet M, Veyradier A, Poullin P, Provôt F, Malot S, et al. Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center. Crit Care Med. 2012 Jan. 40(1):104-11. [Medline].

  20. Becerra E, Scully MA, Leandro MJ, Heelas EO, Westwood JP, De La Torre I, et al. Effect of rituximab on B-cell phenotype and serum B-cell activating factor levels in patients with Thrombotic Thrombocytopenic Purpura. Clin Exp Immunol. 2014 Oct 22. [Medline].

  21. Patriquin CJ, Thomas MR, Dutt T, McGuckin S, Blombery PA, Cranfield T, et al. Bortezomib in the treatment of refractory thrombotic thrombocytopenic purpura. Br J Haematol. 2016 Mar 24. [Medline].

  22. Zhou A, Mehta RS, Smith RE. Outcomes of platelet transfusion in patients with thrombotic thrombocytopenic purpura: a retrospective case series study. Ann Hematol. 2014 Oct 7. [Medline].

  23. Gringauz I, Carmel-Neiderman NN, Mangel T, Portnoy O, Segal G, Goren I. Marked Improvement in Refractory TTP Directly after H. pylori Eradication Therapy. Case Rep Hematol. 2016. 2016:1568586. [Medline]. [Full Text].

  24. Peyvandi F, Scully M, Kremer Hovinga JA, Cataland S, Knöbl P, Wu H, et al. Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura. N Engl J Med. 2016 Feb 11. 374 (6):511-22. [Medline]. [Full Text].

  25. Phase III Trial With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura (HERCULES). ClinicalTrials.gov. Available at https://clinicaltrials.gov/ct2/show/NCT02553317. March 17, 2016; Accessed: May 13, 2016.

  26. Jhaveri KD, Scheuer A, Cohen J, Gordon B. Treatment of refractory thrombotic thrombocytopenic purpura using multimodality therapy including splenectomy and cyclosporine. Transfus Apher Sci. 2009 Aug. 41(1):19-22. [Medline].

  27. Scully M, McDonald V, Cavenagh J, et al. A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura. Blood. 2011 Aug 18. 118(7):1746-53. [Medline].

  28. Shumak KH, Rock GA, Nair RC. Late relapses in patients successfully treated for thrombotic thrombocytopenic purpura. Canadian Apheresis Group. Ann Intern Med. 1995 Apr 15. 122(8):569-72. [Medline].

  29. Roriz M, Landais M, Desprez J, et al; French Thrombotic Microangiopathies Reference Center. Risk Factors for Autoimmune Diseases Development After Thrombotic Thrombocytopenic Purpura. Medicine (Baltimore). 2015 Oct. 94 (42):e1598. [Medline]. [Full Text].

  30. Sikka P, Chopra S, Aggarwal N, Suri V, Chandrasekaran A. Thrombotic thrombocytopenic purpura in the first trimester of pregnancy. Asian J Transfus Sci. 2013 Jan. 7(1):79-80. [Medline]. [Full Text].

 
Previous
Next
 
Differential diagnosis of thrombotic thrombocytopenic purpura/hemolytic-uremic syndrome.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.